Search results for "A2"

showing 10 items of 1101 documents

Topical application of the adenosine A2Areceptor agonist CGS-21680 prevents phorbol-induced epidermal hyperplasia and inflammation in mice

2014

The nucleoside adenosine is a known regulator of immunity and inflammation that mediates, at least in part, the anti-inflammatory effect of methotrexate, an immunosuppressive agent widely used to treat autoimmune inflammatory diseases. Adenosine A2A receptors play a key role in the inhibition of the inflammatory process besides promoting wound healing. Therefore, we aimed to determine the topical effect of a selective agonist, CGS-21680, on a murine model of skin hyperplasia with a marked inflammatory component. Pretreatment with either CGS-21680 (5 μg per site) or the reference agent dexamethasone (200 μg/site) prevented the epidermal hyperplasia and inflammatory response induced by topica…

medicine.medical_specialtyAdenosineAdenosine A2 Receptor AgonistsAdministration Topicalmedicine.medical_treatmentAnti-Inflammatory AgentsAdenosine A2A receptorInflammationDermatologyPharmacologyBiologySkin DiseasesBiochemistryDexamethasoneMicechemistry.chemical_compoundInternal medicinePhenethylaminesmedicineAnimalsMolecular BiologyDexamethasoneCell ProliferationPeroxidaseCGS-21680InflammationHyperplasiaAdenosineAdenosine receptorDisease Models AnimalEndocrinologyCytokinechemistryCytokinesTetradecanoylphorbol AcetateFemaleCollagenEpidermismedicine.symptomWound healingmedicine.drugExperimental Dermatology
researchProduct

Effects of steatosis on drug-metabolizing capability of primary human hepatocytes.

2007

Abstract The suitability of liver grafts discarded for transplantation because of macrosteatosis for preparing human hepatocyte cultures for in vitro drug metabolism studies has been examined. Lower cell viability and yield of isolation procedure were obtained from fatty livers (>40% steatosis) with respect to normal tissue. Significant reductions in 7-ethoxycoumarin O-deethylation (ECOD) and testosterone oxidations were found in hepatocytes prepared from steatotic livers. The potential impact of lipid accumulation on P450 enzymes was studied in vitro by incubation of cultured hepatocytes with long chain free fatty acids (FFA). Treatment of cells with 0.25–3 mM FFA induced dose-dependent ac…

medicine.medical_specialtyCYP3A4CYP1A2General MedicineBiologyCYP2E1Fatty Acids NonesterifiedToxicologymedicine.diseaseTransplantationFatty LiverEndocrinologymedicine.anatomical_structureCytochrome P-450 Enzyme SystemInternal medicineHepatocytemedicineHepatocytesHumansTestosteroneViability assaySteatosisOxidation-ReductionDrug metabolismCells CulturedToxicology in vitro : an international journal published in association with BIBRA
researchProduct

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepati…

2004

Introduction: In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost. Methods: We constructed a Markov model of disease progression in which cohorts of patients received peginterferon α-2a plus ribavirin or interferon α-2b plus ribavirin for 48 weeks (hepatitis C virus [HCV] genotype 1 and non-1 patients with fibrosis) or 24 weeks (genot…

medicine.medical_specialtyCirrhosisGenotypeCost effectivenessCost-Benefit AnalysisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsSensitivity and SpecificityGastroenterologypeginterferon alpha2aPolyethylene Glycolschemistry.chemical_compoundchronic hepatitiInterferonInternal medicineRibavirinmedicineHumansRandomized Controlled Trials as Topicalpha2b interferonAntiviral AgentPharmacologybusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthInterferon-alphavirus diseasesHealth Care CostsHepatitis CHepatitis C Chronicmedicine.diseaseMarkov ChainsRecombinant Proteinsdigestive system diseasesModels EconomicTreatment OutcomechemistryImmunologyQuality of LifePeginterferon alfa-2bDrug Therapy CombinationbusinessPeginterferon alfa-2amedicine.drugPharmacoEconomics
researchProduct

Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence

2020

This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the ex…

medicine.medical_specialtyEdema angioneuròticUrticariamedia_common.quotation_subjectImmunologyeducationGA2LENAngioedema; Center; Excellence; Management; Urticariaurticariacentres of reference and excelenceExcellenceimmune system diseasescentermedicineImmunology and AllergyCenter (algebra and category theory)Angioneurotic edemaskin and connective tissue diseasesmedia_commonudc:616.1Angioedemabusiness.industryangioedemahumanitiesreferenčni centri odličnostiMedicine; Allergy; ImmunologyFamily medicineexcellencemedicine.symptombusinessGlobal Allergy and Asthma European NetworkUrticàriamanagement
researchProduct

Sequential release of TNFα and phospholipase A2 in a rat model of LPS-induced pleurisy

1997

The levels of extracellular phospholipase A2(sPLA2) and TNFα, and cell accumulation were measured in the pleural washings obtained at different times following the induction ofEscherichia colilipopolysaccharide (LPS, 100 μg/cavity) pleurisy in rats. TNFα peaked at 2 hours (3036 ± 160.3 units/ml) and decreased thereafter. Conversely, levels of sPLA2peaked at 48 hours (1.97 ± 0.64 ng/ml) and were increased further (14.02 ± 4.16 ng/ml) by pretreatment with anti-TNFα antibody. Cell accumulation was not affected by antibody pretreatment. These data indicate that the sPLA2enzyme is involved in LPS-induced pleurisy. The enzyme seems not to be stimulated by TNFα which may be involved in the downreg…

medicine.medical_specialtyLipopolysaccharideImmunologypleurisyInflammationchemistry.chemical_compoundPhospholipase A2Downregulation and upregulationInternal medicinemedicineExtracellularlcsh:Pathologyratchemistry.chemical_classificationbiologybusiness.industrylipopolysaccharideCell Biologymedicine.diseaseEndocrinologyEnzymechemistryPleurisyImmunologybiology.proteinTumor necrosis factor alphaphospholipase A2medicine.symptombusinessResearch Articlelcsh:RB1-214Mediators of Inflammation
researchProduct

Recommendations for assessing Patient-Reported Outcomes and Health-Related quality of life in clinical trials on allergy: a GA2LEN taskforce position…

2010

The aim of this Global Allergy and Asthma European Network (GA(2)LEN) consensus report is to provide recommendations for patient-reported outcomes (PROs) evaluation in clinical trials for allergic diseases, which constitute a global health problem in terms of physical, psychological economic and social impact. During the last 40 years, PROs have gained large consideration and use in the scientific community, to gain a better understanding of patients' subjective assessment with respect to elements concerning their health condition. They include all health-related reports coming from the patient, without involvement or interpretation by physician or others. PROs assessment should be performe…

medicine.medical_specialtyPediatricsImmunologyPopulationMEDLINEAlergiaHypersensitivity; Humans; Treatment Outcome; Clinical Trials as Topic; Quality of Life; Outcome Assessment (Health Care); Data CollectionOutcome Assessment (Health Care)Quality of life (healthcare)Outcome Assessment Health CareGlobal healthmedicineHypersensitivityHumansImmunology and AllergyeducationAsmaeducation.field_of_studyClinical Trials as Topicbusiness.industryData CollectionGa2LenGuidelinehumanitiesClinical trialTreatment OutcomeFamily medicineInclusion and exclusion criteriaQuality of LifePosition paperbusinessQualidade de VidaHuman
researchProduct

0128: CHA2DS2-VASc score estimates in-hospital mortality beyond GRACE score after acute myocardial infarction

2016

International audience; Background and aimsCHA2DS2VASc score have recently been suggested to predict death in patients with Atrial Fibrillation (AF). In acute myocardial infarction (AMI), silent AF is more common than symptomatic AF and associated with poor prognosis. In patients with AMI, we aimed to assess the distribution of CHA2DS2VASc score in patients with silent or symptomatic AF and the association of the score with mortality.Methods849 consecutive AMI were prospectively analyzed by continuous ECG monitoring (CEM) 30 sec. Symptomatic AF was defined as any AF occurring on ECG during the hospital stay, resulting in clinical symptoms or need for urgent cardioversion. The population was…

medicine.medical_specialtyPoor prognosismedicine.medical_treatment030204 cardiovascular system & hematologyCardioversion03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineAtrial FibrillationmedicineIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionFramingham Risk ScoreIn hospital mortalitybusiness.industryAtrial fibrillation[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthmyocardial infarctionCHA2DS2–VASc scoreCardiologyCardiology and Cardiovascular MedicinebusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Uneven modulation of the annexin 1 system in osteoblast-like cells by dexamethasone

2007

AbstractWe tested whether glucocorticoids modulated osteoblast expression of the annexin 1 system, including the ligand and two G-coupled receptors termed formyl-peptide receptor (FPR) and FPR-like-1 (FPRL-1). In Saos-2 cells, rapid up-regulation of FPR mRNA upon cell incubation with dexamethasone (0.01–1μM) was observed, with significant changes as early as 2h and a more marked response at 24h; annexin 1 and FPRL-1 mRNA changes were more subtle. At the protein level, dexamethasone provoked a rapid externalization of annexin 1 (maximal at 2h) followed by delayed time-dependent changes in the cell cytosol. Saos-2 cell surface expression of FPR or FPRL-1 could not be detected, even when dexam…

medicine.medical_specialtySaos-2mRNACellBiophysicsBiologyBiochemistryArticleDexamethasoneAnnexinCell Line TumorInternal medicinemedicineHumansReceptors LipoxinReceptorGlucocorticoidsMolecular BiologyDexamethasoneAnnexin A1OsteoblastsInterleukin-6FPRL-1OsteoblastCell BiologyReceptors Formyl PeptideCell biologyCytosolEndocrinologymedicine.anatomical_structureFPRAnnexin A2medicine.drugAnnexin A1Biochemical and Biophysical Research Communications
researchProduct

Progestogens reduce thromboxane production by cultured human endothelial cells.

2011

Objectives Progestogens have been poorly studied concerning their roles in endothelial physiology. Prostanoids are vasoactive compounds, such as thromboxane A2, a potent vasoconstrictor, and prostacyclin, a vasodilator. We examined the effects of two progestogens used clinically, progesterone and medroxyprogesterone acetate, on thromboxane A2 production by cultured human umbilical vein endothelial cells (HUVEC) and investigated the role of progesterone receptors and the enzymes involved in production of thromboxane A2 and prostacyclin. Methods Cells were exposed to 1‐100 nmol/l of either progesterone or medroxyprogesterone acetate, and thromboxane A2 production was measured in culture mediu…

medicine.medical_specialtyUmbilical VeinsAntineoplastic Agents HormonalThromboxaneBlotting WesternGene ExpressionProstacyclinMedroxyprogesterone AcetatePolymerase Chain ReactionProstacyclin synthaseThromboxane receptorThromboxane ProductionThromboxane A2chemistry.chemical_compoundThromboxane A2Hormone AntagonistsCytochrome P-450 Enzyme SystemInternal medicineProgesterone receptorMedicineHumansCyclooxygenase InhibitorsRNA MessengerCells CulturedProgesteronebiologyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyEndothelial CellsGeneral MedicineIntramolecular OxidoreductasesThromboxane B2MifepristoneEndocrinologychemistrycardiovascular systembiology.proteinPyrazolesThromboxane-A synthaseThromboxane-A SynthaseProgestinsbusinessmedicine.drugClimacteric : the journal of the International Menopause Society
researchProduct

Platelet Function During Ticlopidine and Eicosapentaenoic Acid Administration in Patients with Coronary Heart Disease

2010

Antiplatelet drugs have been reported to be useful in unstable angina. This study was designed to investigate the effects of simultaneous administration of ticlopidine and eicosapentaenoic acid (EPA) on platelet function in coronary heart disease (CHD) patients. Ticlopidine significantly reduced platelet aggregation induced by ADP and collagen with no effect on arachidonate metabolism. The aggregation responses to collagen, ADP and arachidonate were not altered significantly by EPA (as fish oil) intake whereas thromboxane A(2) formation was reduced, but not completely inhibited. Combined therapy seems to achieve a more marked degree of inhibition of aggregation together with a fall in the u…

medicine.medical_specialtyUnstable anginabusiness.industryMetaboliteHematologyGeneral MedicinePharmacologyFish oilmedicine.diseaseEicosapentaenoic acidchemistry.chemical_compoundThromboxane A2chemistryInternal medicinemedicineCardiologyPlateletPlatelet activationTiclopidinebusinessmedicine.drugPlatelets
researchProduct